A Phase 1 interventional study of MK-2060 and Placebo in End-Stage Renal Disease (ESRD), End-Stage Kidney Disease (ESKD) and Kidney Failure, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed at 12 sites in Japan. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-14.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Kidney Failure, Chronic by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Merck & Co., Inc.
Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, this one is the 7th largest by enrollment, is one of 2 that started in 2023, is one of 10 in phase 1, and was the 10th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →None of the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc is open now. The open studies under Kidney Failure, Chronic, anywhere →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 18 across the 12 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of MK-2060 after a single dose intravenous (IV) administration in Japanese older participants with end stage renal disease (ESRD) on dialysis. There is no primary hypothesis for this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive MK-2060 50 mg via a single intravenous (IV) infusion over 60-minutes.
Biological: MK-2060
Participants receive a single IV saline infusion over 60 minutes.
Drug: Placebo
Lyophilized powder diluted in normal saline for IV infusion
IV infusion
Also known as: Normal saline
Number of Participants Who Experienced an Adverse Event (AE)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The number of participants who experienced an AE is reported.
Time frame: Up to approximately 164 days
Number of Participants Who Discontinued Study Due to an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The number of participants who discontinued study due to an AE is reported.
Time frame: Up to approximately 164 days
Area Under the Concentration-Time Curve of MK-2060 From Time 0 to Infinity (AUC 0-inf)
Blood samples were collected at specified intervals for the determination of AUC0-inf. AUC0-inf is defined as the area under the concentration-time curve of MK-2060 from time zero to infinity.
Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to Last (AUC0-last)
Blood samples were collected at specified intervals for the determination of AUC0-last. AUC0-last is defined as the area under the plasma concentration-time curve from time zero to time of last measurable concentration of MK-2060.
Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Area Under the Concentration-Time Curve of MK-2060 From Time 0 to 168 Hours Postdose (AUC0-168)
Blood samples were collected at specified intervals for the determination of AUC0-168. AUC0-168 is defined as the area under the concentration-time curve of MK-2060 from time zero to 168 hours.
Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Maximum Concentration (Cmax) of MK-2060
Blood samples were collected at specified intervals for the determination of Cmax. Cmax is defined as the maximum concentration of MK-2060 reached.
Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Concentration at 168 Hours (C168) Postdose of MK-2060
Blood samples were collected at specified intervals for the determination of C168. C168 is defined as the maximum concentration of MK-2060 reached at 168 hours postdose.
Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Time to Maximum Concentration (Tmax) of MK-2060
Blood samples were collected at specified intervals for the determination of Tmax. Tmax is defined as time to the maximum concentration of MK-2060 reached.
Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Time of the Last Measurable Plasma Concentration (Tlast) of MK-2060
Blood samples were collected at specified intervals for the determination of Tlast. Tlast is defined as the time to the last measurable concentration of MK-2060 reached.
Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Terminal Half-Life (t ½) of MK-2060
Blood samples were collected at specified intervals for the determination of t½. t½ is defined as the time required to divide the MK-2060 plasma concentration by two after reaching pseudo-equilibrium, following a single dose of MK-2060.
Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Clearance (CL) of MK-2060
Blood samples were collected at specified intervals for the determination of CL. CL is the volume of plasma from which the study drug is completely removed per unit time.
Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Volume of Distribution (Vz) of MK-2060
Blood samples were collected at specified intervals for the determination of Vz. Vz is the apparent volume of distribution during the terminal phase.
Time frame: Predose, 1, 12, 24, 48 and 52 hours postdose; 5, 12, 15, 22, 60, 90, and up to 157 days post dose; and twice daily on Days 8, 29, 120: pre- and post-dialysis
Change From Baseline in Activated Partial Thromboplastin Time (aPTT)
Blood samples were collected for the determination of aPTT. Change from baseline in aPTT up to 168 hours post dose (pre dialysis) is reported.
Time frame: Baseline and 168 hours post dose
| Milestone | MK-2060 | Placebo |
|---|---|---|
| Started | 12 | 5 |
| Completed | 12 | 5 |
| Not completed | 0 | 0 |
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The number of participants who experienced an AE is reported.
| Participants | MK-2060 | Placebo |
|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 10 | 4 |
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The number of participants who discontinued study due to an AE is reported.
| Participants | MK-2060 | Placebo |
|---|---|---|
| Number of Participants Who Discontinued Study Due to an AE | 0 | 0 |
Blood samples were collected at specified intervals for the determination of AUC0-inf. AUC0-inf is defined as the area under the concentration-time curve of MK-2060 from time zero to infinity.
| hours*nmol/L | MK-2060 | Placebo |
|---|---|---|
| Area Under the Concentration-Time Curve of MK-2060 From Time 0 to Infinity (AUC 0-inf) | 35000 ± 31.8 | — |
Blood samples were collected at specified intervals for the determination of AUC0-last. AUC0-last is defined as the area under the plasma concentration-time curve from time zero to time of last measurable concentration of MK-2060.
| hours*nmol/L | MK-2060 | Placebo |
|---|---|---|
| Area Under the Plasma Concentration-Time Curve of MK-2060 From Time 0 to Last (AUC0-last) | 34500 ± 31.8 | — |
Blood samples were collected at specified intervals for the determination of AUC0-168. AUC0-168 is defined as the area under the concentration-time curve of MK-2060 from time zero to 168 hours.
| hours*nmol/L | MK-2060 | Placebo |
|---|---|---|
| Area Under the Concentration-Time Curve of MK-2060 From Time 0 to 168 Hours Postdose (AUC0-168) | 10100 ± 23.4 | — |
Blood samples were collected at specified intervals for the determination of Cmax. Cmax is defined as the maximum concentration of MK-2060 reached.
| nmol/L | MK-2060 | Placebo |
|---|---|---|
| Maximum Concentration (Cmax) of MK-2060 | 110 ± 26.0 | — |
Blood samples were collected at specified intervals for the determination of C168. C168 is defined as the maximum concentration of MK-2060 reached at 168 hours postdose.
| nmol/L | MK-2060 | Placebo |
|---|---|---|
| Concentration at 168 Hours (C168) Postdose of MK-2060 | 39.0 ± 30.9 | — |
Blood samples were collected at specified intervals for the determination of Tmax. Tmax is defined as time to the maximum concentration of MK-2060 reached.
| hours | MK-2060 | Placebo |
|---|---|---|
| Time to Maximum Concentration (Tmax) of MK-2060 | 1.03 (0.88 to 12.02) | — |
Blood samples were collected at specified intervals for the determination of Tlast. Tlast is defined as the time to the last measurable concentration of MK-2060 reached.
| hours | MK-2060 | Placebo |
|---|---|---|
| Time of the Last Measurable Plasma Concentration (Tlast) of MK-2060 | 3407.34 (2186.65 to 3695.18) | — |
Blood samples were collected at specified intervals for the determination of t½. t½ is defined as the time required to divide the MK-2060 plasma concentration by two after reaching pseudo-equilibrium, following a single dose of MK-2060.
| Days | MK-2060 | Placebo |
|---|---|---|
| Terminal Half-Life (t ½) of MK-2060 | 22.7 ± 18.2 | — |
Blood samples were collected at specified intervals for the determination of CL. CL is the volume of plasma from which the study drug is completely removed per unit time.
| Liters/hour | MK-2060 | Placebo |
|---|---|---|
| Clearance (CL) of MK-2060 | 0.00964 ± 31.8 | — |
Blood samples were collected at specified intervals for the determination of Vz. Vz is the apparent volume of distribution during the terminal phase.
| Liters | MK-2060 | Placebo |
|---|---|---|
| Volume of Distribution (Vz) of MK-2060 | 7.58 ± 28.5 | — |
Blood samples were collected for the determination of aPTT. Change from baseline in aPTT up to 168 hours post dose (pre dialysis) is reported.
| Fold-Change from baseline | MK-2060 | Placebo |
|---|---|---|
| Change From Baseline in Activated Partial Thromboplastin Time (aPTT) | 2.45 (2.27 to 2.63) | 0.97 (0.87 to 1.09) |
Collected over Up to approximately 164 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK-2060 50 mg | 0/12 (0%) | 3/12 (25%) | 9/12 (75%) |
| Placebo | 0/5 (0%) | 1/5 (20%) | 4/5 (80%) |
| Event | MK-2060 50 mg | Placebo |
|---|---|---|
| Mechanical ileusGastrointestinal disorders | 0/12 | 1/5 |
| Peripheral arterial occlusive diseaseVascular disorders | 0/12 | 1/5 |
| Enteritis infectiousInfections and infestations | 1/12 | 0/5 |
| Shunt occlusionInjury, poisoning and procedural complications | 1/12 | 0/5 |
| Shunt stenosisInjury, poisoning and procedural complications | 1/12 | 0/5 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/12 | 0/5 |
| Event | MK-2060 50 mg | Placebo |
|---|---|---|
| DuodenitisGastrointestinal disorders | 0/12 | 1/5 |
| Oedema peripheralGeneral disorders | 1/12 | 1/5 |
| PyrexiaGeneral disorders | 0/12 | 1/5 |
| NasopharyngitisInfections and infestations | 2/12 | 1/5 |
| Immunisation reactionInjury, poisoning and procedural complications | 1/12 | 1/5 |
| Ligament sprainInjury, poisoning and procedural complications | 0/12 | 1/5 |
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 0/12 | 1/5 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/12 | 1/5 |
| Intraductal papillary mucinous neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/12 | 1/5 |
| HaematuriaRenal and urinary disorders | 0/12 | 1/5 |
| Age, Continuous(Years) | MK-2060 | Placebo | Total |
|---|---|---|---|
| Mean | 70.2 ± 7.2 | 66.2 ± 8.3 | 69.0 ± 7.5 |
| Sex: Female, Male(Participants) | MK-2060 | Placebo | Total |
|---|---|---|---|
| Female | 3 | 1 | 4 |
| Male | 9 | 4 | 13 |
| Ethnicity (NIH/OMB)(Participants) | MK-2060 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 12 | 5 | 17 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | MK-2060 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 12 | 5 | 17 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jun 2023 to primary completion in Feb 2024, 8 months.
Results were first posted in Mar 2025, 1 year after primary completion.
Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 8 months is above that.
Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-2060